NanoTemper named one of Germany’s most innovative companies in 2021 by Capital
April 28, 2021For the second year in a row, NanoTemper was named one of the most innovative companies in Germany by Capital magazine. A five out of five star distinction placed NanoTemper in the ranking’s top quartile for innovation. And, with 76 of the 473 award-winning companies hailing from the Munich region, NanoTemper’s global headquarters is in an innovation hotspot.
NanoTemper’s Monolith wins top global design award: iF DESIGN AWARD 2021
April 15, 2021NanoTemper’s newest Monolith instrument has been awarded the globally renowned iF DESIGN AWARD 2021. User-friendly design has always been a core focus in NanoTemper’s product development. NanoTemper’s design approach — beyond thinking about aesthetics — puts the researcher’s needs at the center, ensuring that instruments not only solve big research challenges but also are intuitive and easy-to-use.
NanoTemper Technologies teams up with PharmAI to help researchers spot game-changing drug candidates from millions of possibilities
March 24, 2021NanoTemper Technologies and PharmAI combine competencies to develop biophysical tools that remove costly and time-consuming guesswork from large datasets.
NanoTemper Technologies launches DLS capability with Prometheus Panta, bringing high-resolution, domain-specific stability characterization to biologics
September 24, 2020Prometheus, the new gold standard, now provides clarity to the most challenging stability characterizations
The NanoTemper Story – Chapter 1: The Founding
July 28, 2020As PhD students in Munich, Nanotemper’s founders Philipp Baaske and Stefan Duhr didn’t start their doctorates with the plan to launch a world-wide company that provides innovative instrumentation to academic, government, or industry labs. Yet over ten years later, here they are, still at the helm of our company, and still striving to innovate and satisfy the needs of protein researchers around the globe.
NanoTemper opens tech-forward demo facility in Japan showcasing new technology and offering hands-on experience
July 14, 2020Centrally located in the brand-new, swanky Minato Mirai Centre building in Yokohama Minato Mirai, Japan is NanoTemper Technologies’ newest tech-forward demo facility. Opened to support our distributor partnerships with Central Scientific Commerce (CSC) and M&S Technosystems (M&S), and to meet the growing demand for hands-on experience with our latest technologies for drug discovery, customers come for a personalized experience – to see live demos – and to learn about the most recent applications.
Cyrill Brunner gets Explorer Award for innovative approach to advance drug discovery research using computer modeling
February 21, 2020Meet Cyrill Brunner, Senior PhD candidate at ETH in Zurich, Switzerland (preparing to defend his thesis as we go to press) and one of the 2019 Explorer award recipients. This award is given to individual scientists or teams whose positive contributions to science aligns with NanoTemper’s mission to “do science that matters by always pushing the limits.”
NanoTemper’s presence grows in China – Bigger office opens in Beijing
August 2, 2019We’re growing and thrilled to announce the expansion of our office in Beijing, China. Our mission is to enable everyone to do science that matters by always pushing the limits. Since our inception in 2008, we’ve been “pushing the limits” by going beyond our Munich-based beginnings to meet scientists where they are.
Answering the demands for a new screening tool for drug discovery with Dianthus
April 11, 2019There’s a gap that exists in screening tools for drug discovery — the need for fast, easy to use and flexible devices isn’t being satisfied. Enter Dianthus, introduced to come to the rescue.
NanoTemper Technologies Brings Speed to Drug Discovery Screening, Launches Dianthus System
January 31, 2019NanoTemper Technologies, maker of life science tools for protein characterization, launches its newest system, Dianthus, at the Society for Laboratory Automation and Screening (SLAS2019) conference in Washington, DC. Built to address the demands of drug discovery screening, Dianthus removes the complexity of binding interaction measurements and enables scientists to develop new drugs for every target faster and at lower costs.